You are here

Semaglutide for the treatment of obesity (STEP-programme)

Friday, 25 September 2020, 12:15 - 13:15, Klagenfurt Hall

Chair: L.M. Kaplan, US

L.M. Kaplan, US: Introduction

L.M. Kaplan, US: The role of GLP-1 in DM and obesity

M.J. Davies, UK: From proof of concept: semaglutide

J.P. Wilding, UK: Continuing the STEP journey

L. Czupryniak, PL: Commentary